Cassava Sciences Appoints Three New Members to its Board of Directors
December 07 2023 - 4:01PM
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage
biotechnology company focused on Alzheimer’s disease, today
announced the appointment of three new members to its Board of
Directors, effective immediately.
Claude
Nicaise, MD – Dr. Nicaise has held clinical/regulatory
leadership roles that have resulted in 14 new drug approvals in
various diseases areas, including neuroscience. Dr. Nicaise was a
Senior Vice President of Strategic Development and Global
Regulatory Affairs at Alexion Pharmaceuticals from 2008 to 2014.
From 1983 to 2008, Dr. Nicaise served in various positions of
increasing responsibility at Bristol-Myers Squibb, including senior
positions such as Vice President of Global Development and
Vice-President of Worldwide Regulatory Science and Strategy.
Pierre
Gravier, MS – In July 2023, Mr. Gravier was appointed
Chief Financial Officer of PTC Therapeutics, Inc., a publicly
traded biotechnology company. Mr. Gravier was previously Managing
Director in the healthcare group of Perella Weinberg Partners, a
leading global independent advisory firm that provides strategic,
financial, and tactical advice in connection with executing
mergers, acquisitions and other corporate strategies.
Robert
Anderson, Jr – Mr. Anderson has decades of operational
experience in cybersecurity, counterintelligence, economic
espionage and critical incident response and management. Mr.
Anderson previously led more than 20,000 FBI employees as the
bureau’s Executive Assistant Director of the Criminal, Cyber,
Response and Services Branch— the No. 3 position in the
organization. Mr. Anderson is currently Chairman of the Board and
President of Cyber Defense Labs, an advisory firm focused on
cybersecurity.
“We are fortunate to have these talented
individuals join Cassava Sciences’ Board of Directors,” said Remi
Barbier, Chairman of the Board, President & CEO. “They are
highly respected, astute leaders in their field. Their collective
expertise in drug development, M&A, cybersecurity and dealing
with large, complex governmental agencies will benefit Cassava
Sciences and add a balance of experience and perspectives to the
Board.”
About Cassava Sciences,
Inc.Cassava Sciences is a clinical-stage biotechnology
company based in Austin, Texas. Our mission is to detect and treat
neurodegenerative diseases, such as Alzheimer’s disease. Our novel
science is based on stabilizing—but not removing—a critical protein
in the brain. Simufilam, our lead product candidate, is in clinical
testing in a pair of Phase 3 clinical trials in patients with
mild-to-moderate Alzheimer’s disease dementia. Our product
candidates have not been approved by any regulatory authority, and
their safety, efficacy or other desirable attributes have not been
established.
For more information, please visit:
https://www.CassavaSciences.com
For More Information Contact:
Eric Schoen, Chief Financial Officer(512)
501-2450ESchoen@CassavaSciences.comno
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Apr 2023 to Apr 2024